Autolus Therapeutics Stock Probability of Future Stock Price Finishing Under 4.55
| AUTL Stock | USD 2.98 0.04 1.36% |
Autolus |
Autolus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Autolus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Autolus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Autolus Therapeutics generated a negative expected return over the last 90 days | |
| Autolus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies |
Autolus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Autolus Stock often depends not only on the future outlook of the current and potential Autolus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Autolus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 173.9 M | |
| Cash And Short Term Investments | 239.6 M |
Autolus Therapeutics Technical Analysis
Autolus Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Autolus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Autolus Therapeutics. In general, you should focus on analyzing Autolus Stock price patterns and their correlations with different microeconomic environments and drivers.
Autolus Therapeutics Predictive Forecast Models
Autolus Therapeutics' time-series forecasting models is one of many Autolus Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Autolus Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Autolus Therapeutics
Checking the ongoing alerts about Autolus Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Autolus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Autolus Therapeutics generated a negative expected return over the last 90 days | |
| Autolus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies |
Check out Autolus Therapeutics Backtesting, Autolus Therapeutics Valuation, Autolus Therapeutics Correlation, Autolus Therapeutics Hype Analysis, Autolus Therapeutics Volatility, Autolus Therapeutics History as well as Autolus Therapeutics Performance. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.